Evidence map›Paper›PMID 26948960›Full record

ArticleBMJ open2016

Long-term financing needs for HIV control in sub-Saharan Africa in 2015-2050: a modelling study.

Rifat Atun, Angela Y Chang, Osondu Ogbuoji, Sachin Silva, Stephen Resch, Jan Hontelez, Till Bärnighausen

Abstract read
In one paragraph

Article in BMJ open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rifat AtunHarvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.
Angela Y ChangHarvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.
Osondu OgbuojiHarvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.
Sachin SilvaHarvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.
Stephen ReschHarvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.
Jan HontelezHarvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.
Till BärnighausenHarvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.

Funding

Causal Pathways to population health impact of HIV antiretroviral treatmentR01HD084233 · NICHD · UNIVERSITY OF KWAZULU-NATAL · PI BARNIGHAUSEN, TILL, TANSER, FRANK COURTENEY · 2015 to 2021
$2.3M
NICHD NIH HHS R01 HD084233
6 · The paper itself

Abstract

objectivesTo estimate the present value of current and future funding needed for HIV treatment and prevention in 9 sub-Saharan African (SSA) countries that account for 70% of HIV burden in Africa under different scenarios of intervention scale-up. To analyse the gaps between current expenditures and funding obligation, and discuss the policy implications of future financing needs.

designWe used the Goals module from Spectrum, and applied the most up-to-date cost and coverage data to provide a range of estimates for future financing obligations. The four different scale-up scenarios vary by treatment initiation threshold and service coverage level. We compared the model projections to current domestic and international financial sources available in selected SSA countries.

resultsIn the 9 SSA countries, the estimated resources required for HIV prevention and treatment in 2015-2050 range from US$98 billion to maintain current coverage levels for treatment and prevention with eligibility for treatment initiation at CD4 count of <500/mm(3) to US$261 billion if treatment were to be extended to all HIV-positive individuals and prevention scaled up. With the addition of new funding obligations for HIV--which arise implicitly through commitment to achieve higher than current treatment coverage levels--overall financial obligations (sum of debt levels and the present value of the stock of future HIV funding obligations) would rise substantially.

conclusionsInvesting upfront in scale-up of HIV services to achieve high coverage levels will reduce HIV incidence, prevention and future treatment expenditures by realising long-term preventive effects of ART to reduce HIV transmission. Future obligations are too substantial for most SSA countries to be met from domestic sources alone. New sources of funding, in addition to domestic sources, include innovative financing. Debt sustainability for sustained HIV response is an urgent imperative for affected countries and donors.

Indexed as

AdolescentAdultAfrica South of the SaharaCD4 Lymphocyte CountDeveloping CountriesFemaleFinancial SupportFinancing, GovernmentHealth Care CostsHealth Services Needs and DemandHIV InfectionsHumansInternational CooperationMaleMiddle AgedModels, TheoreticalPUBLIC HEALTH

Identifiers

PMID26948960
PMCPMC4785296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.